WEX Pharmaceuticals, a Vancouver-based company with operations in China, will publish a post hoc analysis of a trial of its painkiller Tectin (tetrodotoxin). For WEX, the problem is that it has run out of money so that it cannot begin a trial on an endpoint that seems promising. More details...
Stock Symbols: (TSX: WXI)
Sorry... this feature or article is only available to subscribers.